You are here
Home > RedHill Biopharma

RedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis

Top-line results are expected in the second quarter of 2017  The randomized, double-blind, placebo-controlled Phase III study is evaluating the safety and efficacy of BEKINDA® 24 mg in patients with acute gastroenteritis and gastritis (the GUARD study) Acute gastroenteritis and gastritis are inflammations of the mucus membranes of the gastrointestinal tract which may lead to nausea, vomiting, diarrhea […]

Top